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into A and B categories and the assignment of T3 N0
M0 tumors to stage IIB. Although these changes
emerged from analysis of a large retrospective database,
the question of whether they reflect the prognosis more
precisely is still a matter of debate.2,3 Thus, a validation
of the new stage grouping by means of retrospective
analysis of a large series of patients has been repeated-
ly postulated.
In the present study we conducted the evaluation of
prognostic value of the current pathologic TNM classi-
fication4 in a group of 586 patients who underwent
complete resection of NSCLC in one institution.
Patients and methods
During the period between January 1, 1991, and June 30,
1995, 698 patients with primary lung cancer underwent pul-
monary resection for lung cancer at the Department of
Thoracic Surgery, Medical University of Gdan´sk, Poland.
Excluded from further analysis were 41 patients with
small cell lung cancer, 17 patients with undifferentiat-
ed or mucoepidermoid cancers, 26 patients with
incomplete nodal dissection or undefined T stage, 13
patients who underwent palliative resection, and 15
patients with insufficient clinical data. The remaining
A precise staging system is of paramount value forselecting therapeutic strategy, estimating prognosis,
and evaluating treatment results in cancer. In non–small
cell lung cancer (NSCLC) the tumor stage is defined by
using the International Union Against Cancer/American
Joint Commission (UICC/AJC) TNM classification.
Since its introduction in the late 1950s, the TNM clas-
sification has undergone several refinements to prog-
nostically select most homogeneous groups. Its last
revision was done in 1997.1 Major modifications in
NSCLC staging included subdivision of stages I and II
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586 patients who met the criteria of this study were
analyzed for their survival. Routine pretreatment stag-
ing within this period included chest radiography in
two planes, examination with a fiberoptic broncho-
scope, chest computed tomography, and abdominal
ultrasonography or computed tomography. Me-
diastinoscopy was not routinely performed. Brain
computed tomography and bone scintigraphy were
done only in case of clinical suspicion of brain or
bone involvement, respectively. In principle, postop-
erative irradiation was not administered; however, a
few patients received radiotherapy according to indi-
vidual decisions made by the treating physicians.
Induction or adjuvant chemotherapy was not per-
formed throughout the analyzed period. Operations
included pulmonary resection (extent presented in
Table I) with the systemic dissection of hilar and
mediastinal lymph nodes. A Naruke map5 was used
for lymph node classification. The pathologic exami-
nation of resected material served as the basis for the
UICC/AJC pTNM classification of 1997.4 Histologic
typing was determined according to the World Health
Organization classification.6 Survival probability and
its 95% confidence interval (CI) were computed by
using the life-table method of Kaplan and Meier, with
the date of the operation set as zero time.
Postoperative 30-day deaths were included in the sur-
vival analysis. The Wilcoxon-Gehan and log-rank sta-
tistics were used for the univariate statistical compar-
isons of survival curves with a 95% CI. The Cox
proportional hazard model was used to calculate the
hazard ratio and its 95% CI for particular stage cate-
gories. Analysis was carried out with a software pack-
age (STATISTICA 5.0, StatSoft, Inc, Tulsa, Okla).
Results
Table I shows the major patient characteristics, and
Table II shows the distribution of particular T, N, and
M designations. Follow-up information was available
for all patients. The median follow-up for the censored
observations was 60 months. By the time of the final
analysis (January 1999), 389 (66%) of the 586 patients
had died (uncensored observations), and 201 (34%)
were alive. A total of 487 (83%) patients died or were
followed up for at least 5 years. The median survival
for the entire group was 29 months, and the 5-year sur-
vival was 36% (95% CI, 34%-38%). Nineteen (3.2%)
patients died within 30 days after the operation.
Postoperative 30-day mortality was related to the stage
of disease; there were 7 (2.1%) deaths in 341 patients
with stage I-IIA disease and 12 (4.9%) deaths in 245
patients with stage IIB-IV disease (P = .06).
The current TNM stage grouping well reflected the
long-term prognostic hierarchy (Table II and Fig 1). In
the new system there was a good distinction between
stage I subsets. Five-year survivals for stages IA and IB
were 66% (95% CI, 51%-81%) and 53% (95% CI,
46%-60%), respectively (IA vs IB: P < .01 and P = .09
for Wilcoxon and log-rank test, respectively). After the
subdivision of stage II, stage IIA was represented by
only 6 (1.0%) patients; therefore, the appropriateness
of this modification could not be verified. Five-year
survival probability in the T3 N0 category (30% [95%
CI, 18%-42%]) was significantly higher than that
found in the new stage IIIA (15% [95% CI, 9%-21%];
T3 N0 vs IIIA: P = .03 and P = .02 for Wilcoxon and
log-rank test, respectively; Fig 2). No difference was
found between T3 N0 (30% [95% CI, 18%-42%]) and
T2 N1 (24% [95% CI, 13%-35%]), the categories con-
stituting new stage IIB (T3 N0 vs T2 N1: P = .73 and
P = .96 for Wilcoxon and log-rank test, respectively).
Within stage IIIA, there was a significant 5-year sur-
vival difference between T3 N2 (6% [95% CI, 0%-
14%]) and the remaining T and N designations (18%
[95% CI, 11%-25%]; T3 N2 vs other IIIA substages: P
= .03 and P = .02 for Wilcoxon and log-rank test,
respectively; Fig 3). Moreover, the 5-year survival in
the T3 N1 category (35% [95% CI, 16%-53%]) was
similar to that found in the new stage IIB (27% [95%
CI, 19%-35%]; T3 N1 vs IIB: P = .53 and P = .87 with
Wilcoxon and log-rank test, respectively). Five-year
survival in T3 N1 tumors was better than that found in
a subset of stage IIIA tumors with N2 disease (12%
[95% CI, 6%-17%]; T3 N1 vs any T N2: P = .17 and P
= .06 with Wilcoxon and log-rank, respectively; Fig 3).
There was a striking difference in 5-year survivals
between clustered stage IIB and T3 N1 tumors (28%
[95% CI, 21%-36%]) and the stage IIIA tumors with
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Table I. Patient characteristics
No. of patients (%)
Age (y)
31-40 9 (1.5)
41-50 85 (15)
51-60 233 (40)
61-70 228 (39)
71-80 31 (5.3)
Sex
Male 463 (79)
Female 123 (21)
Histology
Squamous cell carcinoma 365 (62)
Adenocarcinoma 150 (26)
Large cell carcinoma 48 (8.2)
NSCLC, other 23 (3.9)
Type of operation
Pneumonectomy 241 (41)
Bilobectomy 43 (7.3)
Lobectomy 258 (44)
Lobectomy with sleeve resection 28 (4.8)
Segmentectomy 16 (2.8)
mediastinal nodal involvement (12% [95% CI, 6%-
17%]; IIB + T3 N1 vs any T N2: P < .01 and P = .01
for Wilcoxon and log-rank test, respectively).
Discussion
The aim of the present study was to assess the valid-
ity of the current pathologic TNM classification for
operable NSCLC. We restricted our analysis to a peri-
od from 1991-1995 because within this time the com-
pleteness of clinical data and pathologic staging could
adequately be verified. The relatively long follow-up
period allowed for relevant analysis of survival data.
All patients were treated according to current surgical
standards (ie, with pulmonary resection and dissection
of the regional lymph nodes). The number of pneu-
monectomies, however, was higher compared with
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 6
Jassem et al 1143
Table II.  Five-year survival according to pTNM categories and staging
No. of 5-year 
survivors/ Five-year Hazard
pTNM No. of 5-year survival Pathologic survival ratio
category patients (%) (95% CI) stage (95% CI) (95% CI)
T1 N0 M0 51 (8.7) 16/66% (51%-81%) IA 66% (51%-81%) 1.0
T2 N0 M0 220 (37.5) 69/53% (46%-60%) IB 53% (46%-60%) 1.5 (0.9-2.4)
T1 N1 M0 6 (1.0) 1/17% (0%-46%) IIA 17% (0%-46%) Not able to be evaluated
T2 N1 M0 64 (10.9) 7/24% (13%-35%)
T3 N0 M0 55 (9.4) 8/30% (18%-42%) IIB 27% (19%-35%) 3.7 (2.2-6.1)
T1 N2 M0 11 (1.9) 2/18% (0%-41%)
T2 N2 M0 84 (14.3) 5/13% (6%-21%) IIIA 15% (9%-21%) 4.7 (2.9-7.6)
T3 N1 M0 26 (4.4) 4/35% (16%-53%)
T3 N2 M0 33 (5.6) 2/6% (0%-14%)
T1-3 N3 M0 4 (0.7) 0/0%
T4 N0-2 M0 21 (3.6) 5/24% (16%-42%) IIIB 20% (4%-36%) 4.7 (2.4-8.9)
Any TN M1 11 (1.9) 1/9% (0%-26%) IV 9% (0%-26%) 6.4 (2.8-14.3)
Fig 1. Probability of survival according to clinical stage. Stage IIA is not presented because of a limited number of
patients.
}
}
}
numbers found in other modern series. This feature was
most probably associated with the relatively high num-
ber of patients with stage III disease, usually requiring
more radical approaches. Moreover, in contrast to
many other series, the proportion of patients with ade-
nocarcinoma, a tumor typically located in the periphery
of the lung and managed with a less extensive opera-
tion, was relatively low.
The overall survival obtained in this series was with-
in the range reported by other authors.1,7,8 However, the
results in selected categories were somewhat lower
than those found in some other surgical series.7,9,10 This
variation may be related to the extent of pretreatment
evaluation, as well as to the accuracy of nodal sampling
and pathology reporting.
As expected, the current pTNM classification well
reflected the prognosis in particular stages. The stage I
subdivision was associated with more precise predic-
tion of prognosis within the new substages. Significant
distinction between these categories has been demon-
strated in Mountain’s collected database1 and in a num-
ber of individual studies (Table III).
As in other large surgical series,7-12 the division of
stage II into A and B categories led to an under-repre-
sentation of stage IIA (T1 N1). The proportion of this
stage in our material was 1.0%, and that found in other
surgical series ranged between 0.5% and 4.4%.1,7-12
Because of the small number of patients with stage IIA
disease, we could not verify the clinical relevance of
the stage II subdivision. In the largest retrospective
series with the new classification (5155 patients, with
1892 included in the pTNM analysis), the prognosis of
stages IIA and IIB was of significant difference only in
the clinical classification and not in the pathologic clas-
sification.11 However, a difference between these sub-
stages was detected in a cumulative series of 1910 sur-
gical patients serving as the base for the current
classification1 and in the recently reported Japanese
study of 1310 patients.9 Nevertheless, the value of
stage II subdivision is questionable. Because at least 4
large studies, including the cumulative series of
Mountain, demonstrated no difference in survival
between stages IB and IIA,1,7,9,11 their amalgamation
into one stage might in the future be considered.
Similar to other studies,1,7,9 in our series prognosis of
the T3 N0 category was significantly better than that of
the reshuffled stage IIIA (5-year survivals of 30% and
15%, respectively). At the same time, there was no sig-
nificant difference in survival between patients with T3
N0 and T2 N1 disease. These results support the appro-
priateness of excluding T3 N0 disease from stage IIIA
and its assignment to stage IIB. Because of the limited
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Fig 2.  Probability of survival in the T3 N0 category (n = 55) and stage IIIA (n = 154; T3 N0 vs IIIA: P = .03
and P = .02 for Wilcoxon and log-rank test, respectively).
number of patients with T3 N0-1 tumors in the present
series, no analysis was made in relation to involved
structures (chest wall, main stem bronchus within 2 cm
of the carina, diaphragm, mediastinal structures, and
brachial plexus). It has previously been demonstrated
that the T3 category is heterogeneous; tumors involving
the chest wall carry a significantly better prognosis
than those infiltrating the mediastinum, diaphragm, or
main stem bronchus.9,13
Despite its recent refinement, a large heterogeneity
was found within stage IIIA. The combination of a T3
lesion and involved mediastinal lymph nodes carried a
particularly dismal prognosis, with virtually no patients
experiencing prolonged survival. As in other surgical
series,7,9,10,13,14 within stage IIIA, prognosis in the T3
N2 category was remarkably worse than that found in
the remaining T and N designations. On the other hand,
the prognosis in the T3 N1 category was better than
that in any other IIIA disease and similar to that of T3
N0 tumors. A similar outcome has also been found in
other large surgical series.7,9,10,13-15 Thus, T3 N1 dis-
ease seems to be another candidate to be incorporated
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Table III.  Relevance of new pTNM classification in large surgical series
Relevance of new assignments (P value)
No. of IA vs IIA vs T2 N1 M0
Reference patients IB IIB vs T3 N0 M0 Other findings
Mountain,1 1997 1910* <.05 <.05 >.05 No difference between IB and IIA
Drings and colleagues,11 1997 1892 .001 .114 Not reported No difference between IB and IIA
Inoue and colleagues,9 1998 1310 .001 .02 >.05 No difference between IB and IIA; 
no difference between T3 N0 and T3 N1
Rami-Porta,8 1998 1749† .0006 .12 Not reported No difference between IB and IIA
Present series 586 <.01 Not able to be evaluated .73 No difference between T3 N0 and T3 N1
*Collected database.
†Series included patients who underwent both curative resection and exploratory thoracotomy. Three-year survival is reported.
Fig 3.  Probability of survival in stage IIIA subcategories: T3 N1 (n = 26), T1-2 N2 (n = 95), and T3 N2 (n = 33).
into stage IIB, as already postulated before the last
modification of the TNM system.15
Interestingly, in our series the outcome in IIIA dis-
ease was not much different from that found in stage
IIIB disease. This finding, reported also in other surgi-
cal series,8,9 was probably a result of the small number
of patients with stage IIIB disease. Most important,
however, stage IIIB tumors are only exceptionally
resectable, and therefore the analyzed group of patients
was highly selective and not representative for this cat-
egory; for example, only 4 of 25 patients had N3 dis-
ease, and 10 of 21 patients with T4 disease had N0-1
disease. The same reasons apply to a relatively good
outcome in patients with stage IV disease.
In conclusion, most of our findings confirmed the rel-
evance of the current pTNM classification in determin-
ing the clinical course of patients with resectable
NSCLC. However, despite recent modifications, there
is still a significant heterogeneity that flaws IIIA dis-
ease. Further refinements of this category should there-
fore be considered to place these patients within more
homogeneous staging groups.
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